Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Recommendation of “Hold” by Analysts

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been given a consensus rating of “Hold” by the five ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $27.40.

A number of research firms have recently weighed in on KMTS. BTIG Research reaffirmed a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. The Goldman Sachs Group lowered their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd.

Kestra Medical Technologies Trading Up 0.0%

Kestra Medical Technologies stock opened at $21.26 on Friday. The business has a 50-day simple moving average of $20.69 and a two-hundred day simple moving average of $23.53. The company has a market cap of $1.24 billion, a P/E ratio of -5.37 and a beta of 0.82. Kestra Medical Technologies has a 52-week low of $13.25 and a 52-week high of $30.00. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm had revenue of $24.55 million for the quarter. The firm’s quarterly revenue was up 62.7% compared to the same quarter last year. Analysts predict that Kestra Medical Technologies will post -2.34 EPS for the current year.

Insider Buying and Selling

In related news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $20.96, for a total value of $314,400.00. Following the transaction, the insider directly owned 334,786 shares of the company’s stock, valued at approximately $7,017,114.56. The trade was a 4.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 45,000 shares of company stock valued at $919,050. 3.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. lifted its holdings in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares in the last quarter. Brown Brothers Harriman & Co. raised its holdings in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Kestra Medical Technologies by 7.3% during the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after acquiring an additional 874 shares in the last quarter. Farther Finance Advisors LLC purchased a new stake in shares of Kestra Medical Technologies during the 4th quarter worth approximately $31,000. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in shares of Kestra Medical Technologies by 34.6% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock worth $144,000 after acquiring an additional 1,392 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.